Orchard Therapeutics Highlights Publication In ‘The Lancet’ Of Long-Term Clinical Outcomes With Libmeldy For Treatment Of Children With Early-Onset Metachormatic Leukodystrophy
Administration of one-time hematopoietic stem cell (HSC) gene therapy resulted in sustained, clinically meaningful benefits by preserving cognitive function and motor development in most patients
90% overall survival
JP Morgan Downgrades Orchard Therapeutics to Underweight
JP Morgan analyst Anupam Rama downgrades Orchard Therapeutics (NASDAQ:ORTX) from Neutral to Underweight.
Oppenheimer Maintains Outperform on Orchard Therapeutics, Lowers Price Target to $13
Oppenheimer analyst Kevin DeGeeter maintains Orchard Therapeutics (NASDAQ:ORTX) with a Outperform and lowers the price target from $15 to $13.
Orchard Therapeutics Q3 EPS $(0.29) Down From $(0.20) YoY
Orchard Therapeutics (NASDAQ:ORTX) reported quarterly losses of $(0.29) per share. This is a 45 percent decrease over losses of $(0.20) per share from the same period last year.
Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress
Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced the acceptance of nine abstracts at the upcoming European Society of Gene & Cell Therapy Congress (ESGCT) taking place virtually from
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)